title: Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements.
abstract: Calcitriol (1,25-dihydroxyvitamin D3), the hormonally active metabolite of vitamin D, exerts its anti-proliferative activity in breast cancer (BCa) cells by multiple mechanisms including the downregulation of the expression of estrogen receptor α (ER). We analyzed an ∼3.5 kb ER promoter sequence and demonstrated the presence of two potential negative vitamin D response elements (nVDREs), a newly identified putative nVDRE upstream at -2488 to -2473 bp (distal nVDRE) and a previously published sequence (proximal nVDRE) at -94 to -70 bp proximal to the P1 start site. Transactivation analysis using ER promoter deletion constructs and heterologous promoter-reporter constructs revealed that both nVDREs functioned to mediate calcitriol transrepression. In the electrophoretic mobility shift assay, the vitamin D receptor (VDR) showed strong binding to both nVDREs in the presence of calcitriol, and the chromatin immunoprecipitation assay demonstrated the recruitment of the VDR to the distal nVDRE site. Mutations in the 5' hexameric DNA sequence of the distal nVDRE resulted in the loss of calcitriol-mediated transrepression and the inhibition of protein-DNA complex formation, demonstrating the importance of these nucleotides in VDR DNA binding and transrepression. A putative nuclear factor-Y (NFY) binding site, identified within the distal nVDRE, led to the findings that NFY bound to the distal nVDRE site interfered with the binding of the VDR at the site and reduced calcitriol-mediated transrepression. In conclusion, the ER promoter region contains two negative VDREs that act in concert to bind to the VDR and both nVDREs are required for the maximal inhibition of ER expression by calcitriol. The suppression of ER expression and estrogen-mediated signaling by calcitriol in BCa cells suggests that vitamin D may be useful in the treatment of ER+ BCa.
authors.affiliation: Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5103, USA.
authors.forename: Srilatha
authors.initials: S
authors.lastname: Swami
authors.forename: Aruna V
authors.initials: AV
authors.lastname: Krishnan
authors.forename: Lihong
authors.initials: L
authors.lastname: Peng
authors.forename: Johan
authors.initials: J
authors.lastname: Lundqvist
authors.forename: David
authors.initials: D
authors.lastname: Feldman
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D023081:CCAAT-Binding Factor / Q000378:metabolism; D002117:Calcitriol / Q000494:pharmacology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D011401:Promoter Regions, Genetic; D018167:Receptors, Calcitriol / Q000235:genetics / Q000378:metabolism; D011960:Receptors, Estrogen / Q000235:genetics*; D047488:Retinoid X Receptors / Q000378:metabolism; D030181:Vitamin D Response Element / Q000235:genetics*; D014815:Vitamins / Q000494:pharmacology*
chemical_list: D023081:CCAAT-Binding Factor; D018167:Receptors, Calcitriol; D011960:Receptors, Estrogen; D047488:Retinoid X Receptors; D014815:Vitamins; C402244:nuclear factor Y; D002117:Calcitriol
keywords: breast cancer cells; calcitriol; estrogen receptor; estrogen signaling; nVDREs; transrepression; vitamin D